RE: decent hires2 Mar 2022 11:26
Some quite emotive thoughts being expressed. And not surprising given the lengthy waits for things to come to pass.
Trying to look on the bright side:
1. SlimBiome etc seems to be broadening it's reach via deals with bigger companies, targeted marketing under various guises and now through digital platforms. Which might help as the purely slimming product market seems very competitive.
2. LPldl to me seems our current best product with its positioning as a quasi, if not fully, pharma offering. And, in Monday's update, Probiotix showed a more healthy EBITDA profit (more than 2x) compared to SlimBiome (Prebiotix).
3. SweetBiotix recalls to mind a country lyric "If tomorrow never comes". But hopefully it will come. And will provide a boost when a deal is finally done. Perhaps SOH could set out key milestones to be achieved in order for a deal to take place.
4. The value of SkinBiotix is, for me, a difficult asset to price in, as its value has been quite volatile (Γ bit like Opti when it shot up to Β£1.25 ish). Mainly because SBTX is only just getting to revenue stage.
Comments/criticisms welcome. Cheers. Martin.